Related Experiment Videos
Persistence with teriparatide in patients with osteoporosis: the UK experience
N K Arden1, S Earl, D J Fisher
1MRC Epidemiology Resource Centre, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK. nka@mrc.soton.ac.uk
Insights
Persistence with teriparatide treatment in the UK is high, with 87% of patients continuing therapy at 12 months. This indicates a favorable long-term adherence for osteoporosis management.
Area of Science:
- Endocrinology
- Pharmacology
- Bone Metabolism
Background:
- Osteoporosis poses a significant public health challenge, necessitating effective long-term treatment strategies.
- Teriparatide is a key therapeutic agent for osteoporosis management.
Purpose of the Study:
- To evaluate the 12-month persistence rate of teriparatide in a UK patient cohort.
- To identify factors influencing treatment discontinuation.
Main Methods:
- Retrospective analysis of teriparatide prescription data in the UK.
- Inclusion of 1,104 patients prescribed teriparatide since its launch.
- Assessment of treatment start and discontinuation dates and reasons.
Main Results:
- Median teriparatide use was 252 days.
- At 12 months post-initiation, 87% of patients demonstrated treatment persistence.
- Adverse events led to discontinuation in 3.8% of patients.
Conclusions:
- Teriparatide exhibits high 12-month persistence rates in UK patients.
- Persistence appears superior to existing oral osteoporosis therapies.
- High persistence optimizes therapeutic effectiveness in high-risk osteoporosis patients.
Introduction:
The objective of this paper was to determine the persistence with teriparatide at 12 months in all patients in the UK who were prescribed the treatment since its launch.
Methods:
Virtually all patients prescribed teriparatide in the UK receive treatment through Healthcare at Home, Basingstoke, UK. Data was obtained to assess the start date, discontinuation date and reason for discontinuation in all patients receiving teriparatide since its launch. Persistence was defined as the number of patients continuing treatment.
Results:
A total of 1,104 patients were included in the analysis. The median duration of use in all patients was 252 days. Of the 435 patients who were at least 12 months post-initiation of treatment, persistence was 87%. Forty-two patients (3.8%) had discontinued treatment due to adverse events.
Conclusions:
This study demonstrates that persistence with teriparatide at 12 months is very high and is probably greater than that of existing oral therapies for osteoporosis. The reasons for the high persistence rates seen with teriparatide are likely to be multi-factorial. The high persistence rates should help to optimise the effectiveness of therapy in this group of high-risk patients.
Related Concept Videos
01:40Bone Remodeling
01:31Osteoclasts in Bone Remodeling
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...